BrunoCarneiro DeMedeirosMD
Hematology • Stanford, CAAssistant Professor, Medicine - Hematology, Stanford University Medical Center
Are you Dr. Medeiros?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 51 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
269 Campus Dr
CCSR 1155
Stanford, CA 94305Phone+1 650-723-5007Fax+1 650-724-5203- Is this information wrong?
Summary
- Dr. Bruno Medeiros, MD is a hematologist in Stanford, California. He is currently licensed to practice medicine in California and Colorado. He is affiliated with Stanford Health Care and is an Assistant Professor at Stanford University Medical Center.
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 2002 - 2005- University of ColoradoResidency, Internal Medicine, 2000 - 2002
University of ConnecticutInternship, Internal Medicine, 1999 - 2000
Federal University of Parana Faculty of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2006 - 2024
CO State Medical License 2002 - 2005
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia Start of enrollment: 2007 Dec 01
- Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2005 Jul 01
- Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) Start of enrollment: 2009 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-...Carla Biesdorf, Xiaowen Guan, Satya R Siddani, Nils Boehm, Bruno C Medeiros, Toshihiko Doi, Maja de Jonge, Drew Rasco, Rajeev M Menon, Akshanth R Polepally, David Hoffman> ;Cancer Chemotherapy and Pharmacology. 2024 Apr 1
- 1 citationsA randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, John M Pagel, Jerald P Radich, Min Fang, David A Rizzieri, Guido Marcucci, Stephen A Strickland, Mark R Litz...> ;Leukemia. 2024 Jan 1
- 4 citationsActivity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.Stephen K Tahir, Emiliano Calvo, Benedito A Carneiro, Junichiro Yuda, Aditya Shreenivas, Mojca Jongen-Lavrencic, Eelke Gort, Kenichi Ishizawa, Daniel Morillo, Carla Bi...> ;Blood. 2023 Apr 27
- Join now to see all
Press Mentions
Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid LeukemiaJune 14th, 2016
Hospital Affiliations
Stanford Health CarePalo Alto, California
